FDA grants conditional acceptance of LYRFIGTU brand name
Elevar Therapeutics says the FDA granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib, which is under FDA Priority Review.
Elevar Therapeutics, Inc., a subsidiary of HLB Co., Ltd. (028300.KQ), said Tuesday that the U.S. Food and Drug Administration has granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib, which is currently under FDA Priority Review as a treatment option.